The HTAC recommends the DOH financing and inclusion of Covovax in the Philippine National Deployment and Vaccination Plan for COVID-19 (NDVP) for the general population aged 18 years and above. COVID-19 Vaccines under Emergency Use Authorization (EUA) The Food and Drug Administration (FDA) issues Emergency Use Authorization (EUA) for vaccines and drugs during public health emergencies which allows a shorter continue reading : HTAC Guidance for Health Care Providers: COVID-19 Vaccine Covovax
HTAC Guidance for Health Care Providers: COVID-19 Vaccine Sputnik V
The HTAC retains its recommendation for DOH to finance and include Sputnik V in the Philippine National Deployment and Vaccination Plan for COVID-19 for the general population aged 18 years and above. COVID-19 Vaccines under Emergency Use Authorization (EUA) The Food and Drug Administration (FDA) issues Emergency Use Authorization (EUA) for vaccines and drugs during public health emergencies which allows a continue reading : HTAC Guidance for Health Care Providers: COVID-19 Vaccine Sputnik V
Preliminary Recommendation for the Inclusion of Sambong 250mg Tablets as Anti-Urolithiasis
Document link: MEDICINES RECOMMENDED FOR INCLUSION IN THE PHILIPPINE NATIONAL FORMULARY (PNF) (Proponents may submit appeals to hta@doh.gov.ph until 04 January 2022 using the prescribed appeal form.) Document Preview:
Evidence brief for 13 December to 17 December 2021
For the period of 13 December 2021 to 17 December 2021 Reviewed by: Department of Health (DOH) – Health Technology Assessment Unit (HTAU) Document Link: 13 December to 17 December 2021
Preliminary Recommendation on Emtricitabine + Tenofovir Disoproxil Fumarate fixed-dose combination as Oral Pre-Exposure Prophylaxis (PrEP)
Document link: MEDICINES RECOMMENDED FOR INCLUSION IN THE PHILIPPINE NATIONAL FORMULARY (PNF) (Proponents may submit appeals to hta@doh.gov.ph until 30 December 2021.) Document Preview: